Literature DB >> 15375520

The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.

Edgar Mendoza-Gamboa1, Doris R Siwak, Ana M Tari.   

Abstract

We showed that the HER2/Grb2/Akt pathway induces all-trans retinoic acid (ATRA) resistance in breast cancer cells by suppressing the DNA binding activity of retinoic acid receptors (RAR). AP-1 activation was shown to induce ATRA resistance. Here, we determined whether AP-1 binding activity is correlated with ATRA resistance in HER2-overexpressing cells. Inhibition of HER2/Grb2/Akt decreased AP-1 binding activity in HER2-transfected cells, but increased AP-1 activity in cells that are naturally HER2-overexpressing. Since HER2/Grb2/Akt inhibition sensitized both cell types to ATRA, our results indicate that, unlike RAR, AP-1 binding activity is not correlated with ATRA sensitivity in HER2-overexpressing breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375520

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells.

Authors:  Valerie S Hawthorne; Wen-Chien Huang; Christopher L Neal; Ling-Min Tseng; Mien-Chie Hung; Dihua Yu
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

2.  Heregulin-beta promotes matrix metalloproteinase-7 expression via HER2-mediated AP-1 activation in MCF-7 cells.

Authors:  Guogang Yuan; Lu Qian; Lun Song; Ming Shi; Dan Li; Ming Yu; Meiru Hu; Beifen Shen; Ning Guo
Journal:  Mol Cell Biochem       Date:  2008-07-04       Impact factor: 3.396

3.  Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.

Authors:  J B Patel; J Mehta; A Belosay; G Sabnis; A Khandelwal; A M H Brodie; D R Soprano; V C O Njar
Journal:  Br J Cancer       Date:  2007-03-27       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.